INR 72.5
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 652.27 Million INR | 16.21% |
2022 | 561.28 Million INR | 105.12% |
2021 | 273.64 Million INR | -7.85% |
2020 | 296.94 Million INR | 47.61% |
2019 | 201.17 Million INR | -80.01% |
2018 | 1 Billion INR | -0.53% |
2017 | 1.01 Billion INR | -25.72% |
2016 | 1.36 Billion INR | 0.92% |
2015 | 1.34 Billion INR | 6.17% |
2014 | 1.27 Billion INR | -23.46% |
2013 | 1.66 Billion INR | -13.63% |
2012 | 1.92 Billion INR | 24.6% |
2011 | 1.54 Billion INR | 89.51% |
2010 | 814.32 Million INR | 88.84% |
2009 | 431.23 Million INR | 9.71% |
2008 | 393.05 Million INR | 0.09% |
2007 | 392.72 Million INR | -12.47% |
2006 | 448.69 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -808.39 Million INR | -223.93% |
2023 Q1 | - INR | -100.0% |
2023 Q2 | 525.05 Million INR | 0.0% |
2023 FY | 652.27 Million INR | 16.21% |
2023 Q4 | 652.27 Million INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2022 Q4 | 561.28 Million INR | 0.0% |
2022 FY | 561.28 Million INR | 105.12% |
2022 Q2 | 403.88 Million INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2022 Q3 | - INR | -100.0% |
2021 Q2 | 284.88 Million INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 Q4 | 273.64 Million INR | 0.0% |
2021 FY | 273.64 Million INR | -7.85% |
2021 Q3 | - INR | -100.0% |
2020 Q2 | 211.11 Million INR | 0.0% |
2020 FY | 296.94 Million INR | 47.61% |
2020 Q4 | 296.94 Million INR | 0.0% |
2020 Q1 | - INR | -100.0% |
2019 Q3 | - INR | -100.0% |
2019 FY | 201.17 Million INR | -80.01% |
2019 Q1 | - INR | -100.0% |
2019 Q2 | 1.05 Billion INR | 0.0% |
2019 Q4 | 201.17 Million INR | 0.0% |
2018 FY | 1 Billion INR | -0.53% |
2018 Q4 | 1 Billion INR | 0.0% |
2018 Q1 | - INR | 0.0% |
2017 FY | 1.01 Billion INR | -25.72% |
2016 FY | 1.36 Billion INR | 0.92% |
2015 FY | 1.34 Billion INR | 6.17% |
2014 FY | 1.27 Billion INR | -23.46% |
2013 FY | 1.66 Billion INR | -13.63% |
2012 FY | 1.92 Billion INR | 24.6% |
2012 Q2 | 2.28 Billion INR | 0.0% |
2012 Q4 | 1.92 Billion INR | 0.0% |
2011 FY | 1.54 Billion INR | 89.51% |
2010 FY | 814.32 Million INR | 88.84% |
2009 FY | 431.23 Million INR | 9.71% |
2008 FY | 393.05 Million INR | 0.09% |
2007 FY | 392.72 Million INR | -12.47% |
2006 FY | 448.69 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 95.992% |
Hester Biosciences Limited | 3.59 Billion INR | 81.855% |
Aarti Drugs Limited | 11.5 Billion INR | 94.33% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 92.094% |
Albert David Limited | 1.15 Billion INR | 43.285% |
Alembic Limited | 1.43 Billion INR | 54.453% |
Alkem Laboratories Limited | 48.6 Billion INR | 98.658% |
Bajaj HealthCare Limited | 4.86 Billion INR | 86.6% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -125.859% |
Brooks Laboratories Limited | 248.6 Million INR | -162.38% |
Eris Lifesciences Limited | 38.26 Billion INR | 98.296% |
FDC Limited | 3.7 Billion INR | 82.415% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 87.41% |
Gufic Biosciences Limited | 5.59 Billion INR | 88.352% |
Hikal Limited | 12.99 Billion INR | 94.981% |
Ind-Swift Limited | 13.45 Billion INR | 95.151% |
Innova Captab Limited | 4.89 Billion INR | 86.688% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 89.694% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -119.8% |
Jubilant Pharmova Limited | 61.27 Billion INR | 98.935% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 39.297% |
Lupin Limited | 96.23 Billion INR | 99.322% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 66.995% |
Medico Remedies Limited | 438.24 Million INR | -48.839% |
Morepen Laboratories Limited | 4.45 Billion INR | 85.374% |
Nectar Lifesciences Limited | 11.21 Billion INR | 94.185% |
Orchid Pharma Limited | 3.84 Billion INR | 83.032% |
Procter & Gamble Health Limited | 2.56 Billion INR | 74.532% |
RPG Life Sciences Limited | 1.38 Billion INR | 52.74% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -1.304% |
Sigachi Industries Limited | 2.53 Billion INR | 74.231% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 95.371% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 67.935% |
Themis Medicare Limited | 1.88 Billion INR | 65.442% |
Unichem Laboratories Limited | 8.06 Billion INR | 91.916% |
Vaishali Pharma Limited | 371.16 Million INR | -75.739% |
Wanbury Limited | 3.15 Billion INR | 79.329% |
Windlas Biotech Limited | 1.76 Billion INR | 62.995% |
ZIM Laboratories Limited | 2.08 Billion INR | 68.652% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 71.509% |
Ipca Laboratories Limited | 33.74 Billion INR | 98.067% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.645% |
Venus Remedies Limited | 1.39 Billion INR | 53.168% |
Sakar Healthcare Limited | 1.26 Billion INR | 48.366% |
Aurobindo Pharma Limited | 152.2 Billion INR | 99.571% |
Divi's Laboratories Limited | 18.99 Billion INR | 96.565% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 82.184% |
Mankind Pharma Limited | 23.87 Billion INR | 97.268% |
Sequent Scientific Limited | 8.27 Billion INR | 92.117% |
Laurus Labs Limited | 42.71 Billion INR | 98.473% |
Neuland Laboratories Limited | 5.49 Billion INR | 88.137% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 93.908% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 98.998% |
Zydus Lifesciences Limited | 71.79 Billion INR | 99.091% |
Amrutanjan Health Care Limited | 783.82 Million INR | 16.782% |
Wockhardt Limited | 39.87 Billion INR | 98.364% |
Bal Pharma Limited | 2.51 Billion INR | 74.026% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 99.39% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 69.069% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -308.208% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 81.393% |
Shilpa Medicare Limited | 12.93 Billion INR | 94.956% |
Valiant Laboratories Limited | 1.05 Billion INR | 38.363% |
Ajanta Pharma Limited | 10.71 Billion INR | 93.91% |
Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 62.125% |
Granules India Limited | 22.95 Billion INR | 97.158% |
Medicamen Biotech Limited | 940.36 Million INR | 30.636% |
Syncom Formulations (India) Limited | 1.16 Billion INR | 44.021% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.884% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 99.205% |
NATCO Pharma Limited | 10.53 Billion INR | 93.807% |
Suven Life Sciences Limited | 148.62 Million INR | -338.888% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 78.067% |
Strides Pharma Science Limited | 37.68 Billion INR | 98.269% |
Indoco Remedies Limited | 10.34 Billion INR | 93.693% |
Alpa Laboratories Limited | 307.12 Million INR | -112.384% |
Lasa Supergenerics Limited | 541.92 Million INR | -20.363% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 83.244% |